Clinical trials: Renal Tumors
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Kidney Cancer
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
The goal of this clinical research study is to compare the effectiveness of Afinitor (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma (kidney cancer).
- Trial name
- NCT01185366
- Testing
- Everolimus, Sunitinib
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Cancer
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
This is a Phase 1b, open-label, multi-center, multiple-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D) of avelumab (MSB0010718C) in combination with axitinib…
- Trial name
- NCT02493751
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 21 sites in United States, Japan and 1 more
- Volunteers
- 55 people
- Sponsor
- Pfizer
RCC, Renal Cell Cancer, Partial Nephrectomy
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
Renal tumors are common urological cancers, with over 430,000 new cases and more than 170,000 deaths globally in 2020. In China, renal cancer ranks third among urological malignancies, with an increasing incidence.
- Trial name
- NCT06908902
- Testing
- partial nephrectomy with main or branch renal artery clamping, partial nephrectomy with zero renal artery clamping
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pediatric Disorder, Hydronephrosis in Children
Effect of Concomitant Bladder Neck Incision and Urethral Valve Ablation on Surgical Re-intervention Rate for Patients With Posterior Urethral Valve
To determine the short-term effects of concurrent valve ablation and bladder neck incision on re-intervention rate for patients with posterior urethral valve.
- Conditions
- Pediatric Disorder, Hydronephrosis in Children, Hydronephrosis, Secondary, Hydronephrosis Congenital
- Trial name
- NCT05087537
- Testing
- Valve ablation, Valve ablation and bladder neck incision
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Mansoura University
Chronic Myelogenous Leukemia, Malignant Melanoma
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical…
- Conditions
- Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
- Trial name
- NCT02829775
- Testing
- Pegylated Interferon Alfa-2a, Recombinant Interferon Alfa 2a
- Where
- 8 sites in Bulgaria, Canada and 5 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Metabolomics, Renal Cell Carcinoma
Biomarkers of Response to Systemic Treatments in FH-deficient RCC
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of RCC characterized by germline/somatic mutation of the fumarate hydratase (FH) gene, and is an extremely aggressive tumor, with a propensity…
- Conditions
- Metabolomics, Renal Cell Carcinoma, FH-Deficient RCC, Systemic Treatments
- Trial name
- NCT05243173
- Testing
- Sequencing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Renal Cell Carcinoma
NCCN Renal Cell Registry
This study will consist of three parts: 1) a retrospective chart review of patients treated for mRCC from July 2013 until the start of the educational intervention; 2) an educational program for DCN community oncology providers…
- Trial name
- NCT02677337
- Testing
- chart abstraction, Educational Program
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Duke University
COVID-19 Infection, Genitourinary Cancer
Impact of COVID-19 on GU Disease
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: Complete an Online COVID-19 Questionnaire.
- Conditions
- COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
- Trial name
- NCT04761107
- Where
- United States
- Volunteers
- 15,240 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Chronic Renal Failure
The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis
To investigate the biocompatibility of the peritoneal dialysis (PD) solution balance in comparison to the conventional PD solution in APD(automated peritoneal dialysis) patients using the APD cycler sleep•safe.
- Trial name
- NCT01753154
- Testing
- Solution B (balance PD solution), Solution A (conventional PD solution)
- Where
- 7 sites in Poland, Spain
- Volunteers
- 25 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Esophageal Cancer, Kidney Cancer
GI Organ Tracking Via Balloon Applicators
The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.
- Conditions
- Esophageal Cancer, Kidney Cancer, Larynx Cancer, Liver Cancer
- Trial name
- NCT05471401
- Testing
- Balloon-tipped catheter
- Sponsor
- Washington University School of Medicine
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell…
- Trial name
- NCT05239728
- Testing
- Belzutifan, Pembrolizumab
- Where
- 285 sites in United States, Australia and 30 more
- Volunteers
- 1,800 people
- Sponsor
- Merck Sharp & Dohme LLC
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Renal Cell Cancer Metastatic, Kidney Cancer
Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue
Fatigue is a prevalent adverse event associated with systemic therapy using tyrosine kinase inhibitors (TKIs). Meldonium, a fatty acid oxidation inhibitor, modifies the carnitine pathway, a nutrient critical for fat metabolism.
- Conditions
- Renal Cell Cancer Metastatic, Kidney Cancer, Fatigue Related to Cancer Treatment
- Trial name
- NCT06648902
- Testing
- meldonium
- Where
- 3 sites in Albania, Azerbaijan and 1 more
- Volunteers
- 60 people
- Sponsor
- Kidney Cancer Research Bureau
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of…
- Conditions
- Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03541902
- Testing
- Cabozantinib, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cell Carcinoma, Circulating Tumor Cell
Circulating Tumor Cell Reducing No-touch Nephrectomy
This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an…
- Trial name
- CITO-CERENE (NCT05070637)
- Testing
- No-touch laparoscopic radical nephrectomy, Conventional laparoscopic radical nephrectomy, Laparoscopic total nephrectomy control arm
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Hospital de Santa Maria, Portugal
Colon Cancer, Lung Cancer
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Background: Fluciclatide is a small cyclic peptide containing the RGD tri-peptide, which preferentially binds with high affinity to alpha(v)beta(3) integrins, which are up-regulated in and may regulate angiogenesis.
- Conditions
- Colon Cancer, Lung Cancer, Cervical Cancer, Renal Cell Carcinoma
- Trial name
- NCT01176500
- Testing
- (18)Fluciclatide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.